A5033244041- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- Acute Myeloid Leukemia Research
- T-cell and Retrovirus Studies
- Vector-Borne Animal Diseases
- Neutropenia and Cancer Infections
- Chromatin Remodeling and Cancer
- Fungal and yeast genetics research
- Genomics and Chromatin Dynamics
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Neurobiology and Insect Physiology Research
- DNA Repair Mechanisms
- Insect Resistance and Genetics
- RNA modifications and cancer
- Genetics, Aging, and Longevity in Model Organisms
- Click Chemistry and Applications
- Plant Pathogenic Bacteria Studies
- Cancer, Lipids, and Metabolism
- Chronic Lymphocytic Leukemia Research
- CRISPR and Genetic Engineering
- Telomeres, Telomerase, and Senescence
- Brain Metastases and Treatment
- RNA regulation and disease
- Viral-associated cancers and disorders
Daiichi-Sankyo (Japan)
2015-2022
Daiichi Sankyo (United Kingdom)
2019
Chiba University
2003-2004
Japan Science and Technology Agency
1999-2000
Prefectural University of Hiroshima
1998
The University of Tokyo
1993-1998
Institute of Agrobiological Sciences
1998
University of California, Davis
1998
Although global H3K27me3 reprogramming is a hallmark of cancer, no effective therapeutic strategy for H3K27me3-high malignancies harboring EZH2WT/WT has yet been established. We explore epigenome and transcriptome in EZH2WT/Mu aggressive lymphomas show that mutual interference compensatory function co-expressed EZH1 EZH2 rearrange their own genome-wide distribution, thereby establishing restricted chromatin gene expression signatures. Direct comparison leading compounds introduces potency...
Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor prognosis and few treatment options for patients relapsed, recurrent, or refractory disease. We evaluated the efficacy safety of valemetostat, a potent enhancer zeste homolog 2 (EZH2) EZH1 inhibitor, in treating relapsed (R/R) ATL. This multicenter phase trial enrolled R/R ATL (acute, lymphoma, unfavorable chronic type). Patients received valemetostat 200 mg/day orally until progressive disease unacceptable...
Polycomb repressive complex 2 (PRC2) methylates histone H3 lysine 27 and represses gene expression to regulate cell proliferation differentiation. Enhancer of zeste homolog (EZH2) or its close EZH1 functions as a catalytic subunit PRC2, so there are two PRC2 complexes containing either EZH2 EZH1. Tumorigenic synthetic lethality with some subunits SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling have been observed. However, little is known about the function in tumorigenesis....
Background Structural changes in chromatin play essential roles regulating eukaryotic gene expression. Silencing, potent repression of transcription Saccharomyces cerevisiae , occurs near telomeres and at the silent mating‐type loci, as well rDNA loci. This type relates to condensation that heterochromatin multicellular organisms. Anti‐silencing is a reaction by which silenced loci are de‐repressed. Genetic studies revealed several factors participate anti‐silencing reaction. However,...
Abstract Introduction: Enhancer of zeste homolog 2 (EZH2) and its close homolog, EZH1, catalyze the attachment 3 methyl groups to histone H3 at lysine 27. Altered EZH2 expression is implicated in etiology non‐Hodgkin lymphomas (NHLs). Valemetostat tosylate (DS‐3201b; valemetostat) a novel, potent, selective dual inhibitor EZH1. This article protected by copyright. All rights reserved.
Abstract Mantle cell lymphoma (MCL) is a rare subtype of non‐Hodgkin's lymphoma, which characterized by overexpression cyclin D1. Although novel drugs, such as ibrutinib, show promising clinical outcomes, relapsed MCL often acquires drug resistance. Therefore, alternative approaches for refractory and are needed. Here, we examined whether inhibitor enhancer zeste homologs 1 2 (EZH1/2), OR‐S1 (a close analog the clinical‐stage compound valemetostat), had an antitumor effect on cells. In...
Transcription elongation factor S-II stimulates cleavage of nascent transcripts generated by RNA polymerase II stalled at transcription arrest sites. In vitro experiments have shown that this action promotes to read through these This S-II-mediated is thought be necessary, but not sufficient, promote read-through in thein systems. Therefore,Saccharomyces cerevisiae strains expressing mutant proteins with different activities were used study both the and stimulation determine which functions...
Abstract Xanthomonas campestris pv. and X. oryzae pv, contain the 1428 base pair hrpX gene whose product is involved in regulation oi hrp genes required for pathogericity, non‐host hypersensitivity non‐permissibility of compatible host defence responses. Previous Southern blot hybridization studies have suggested that conserved several pathovars oryzae. strains. We confirmed extended these findings using amplification by polymerase chain reaction, coupled with analyses. Sixteen distinct 12...
Background: Milademetan (DS-3032b) is a small-molecule MDM2 inhibitor that activates p53 and induces apoptosis by disrupting the MDM2-p53 interaction. has demonstrated single-agent antileukemic activity in preclinical clinical studies AML. AZA, hypomethylating agent, used to treat AML myelodysplastic syndromes upregulating epigenetically silenced genes cells. We conducted study of milademetan combination with AZA because both agents modulate gene expression related cell growth or apoptosis....
We isolated a Schizosaccharomyces pombe (Sz. ) gene encoding the counterpart of TFIIH subunit Homo sapiens (H. p44 and Saccharomyces cerevisiae (S. SSL1, we named this product p47. Contrary to case which is an essential S. cerevisiae, p47 not for viability Sz. pombe. The deduced amino acid sequence revealed that highly conserved during evolution. Comparison primary structures differences in predicted positions introns Caenorhabditis elegans (C. found genome project. A charged cluster...